Hypofractionated radiation therapy (RT) has become an intriguing treatment option for cancer thanks to its shortened therapy schedule relative to conventional RT. A recently presented analysis has shown it also largely matches up with conventional RT on cure rates and side effects when used for low-risk prostate cancer.
A steroidal pain-management treatment used during radiation therapy for bone metastases has made good on its earlier promise, meaningfully outperforming placebo in a double-blind, randomized phase 3 trial.
Retroactively implementing ACR’s 2014 LungRADS classification criteria, an academic medical center increased the positive predictive value in a CT lung-screening cohort of more than 1,600 patients by a factor of 2.5—without driving an increase in surgeries following false negatives.
A new MRI technique being studied at Memorial Sloan Kettering Cancer Center in New York City could cut the time needed to reveal whether a tumor is responding to treatment from a matter of weeks to just a few days.
Cell-based therapies that exploit modified human cells to treat cancer have been a promising area of research, but issues remain. Specifically, the driver-less cells are difficult to target, especially in tissues deep in the body.
Researchers at Cedars-Sinai Medical Center in Los Angeles are working on a technique that could diagnose brain tumors and treat the cancer with a combination of an MRI “virtual biopsy” and nano-scale drugs.